# VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms

> **NCT03944369** · NA · TERMINATED · sponsor: **Kaleido Biosciences** · enrollment: 3 (actual)

## Conditions studied

- Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects

## Interventions

- **OTHER:** KB109
- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT03944369
- **Lead sponsor:** Kaleido Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-27
- **Primary completion:** 2020-06-16
- **Final completion:** 2020-06-16
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** COVID-19 pandemic
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944369, "VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03944369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*